About Genoa Ventures
Genoa Ventures is a venture capital firm founded in 2014. It is primarily based out of San Francisco, United States. As of Jul 2026, Genoa Ventures is an active investor, having invested in 31 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Food and Agriculture Tech. Most recently it participated in the $***** Series B round of Epitel Overall, Genoa Ventures portfolio has seen 1 IPO and 5 acquisitions including key companies like Fortune, Caribou Biosciences and Zymergen. A lot of funds co-invest with Genoa Ventures, with names like Vertical Venture Partners sharing a substantial percentage of its portfolio. Genoa Ventures has team of 7 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Genoa Ventures' List of Top Investments
Genoa Ventures has a portfolio of 31 companies. Their most notable investments are in Alida Biosciences and Hermes Bioscience.Their portfolio spans across United States, United Kingdom and France. They have invested in Life Sciences, High Tech, Food and Agriculture Tech and 7 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by Genoa Ventures:
Developer of gene editing technologies for improved tropical crop production. The company focuses on improving crops to be tastier and hardier. It aims to make crops less reliant on pesticides and more resilient to climate change. The company’s technology supports farmers, equipping them against climate change. It helps them to increase their yields.
Key facts about Tropic Biosciences
2. Fortune
Key facts about Fortune
- Founded Year: 1929
- Location: New York City (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 3,010 as on Apr 30, 2026
- Investors: Genoa Ventures, Altair Capital and 2 Others
- Highlight: Acquired
3. Mission Bio
Provider of a single-cell multi-omics platform for genotypic and phenotypic analysis. The company's proprietary Tapestri platform enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins for the precise treatment of cancer. Also, it offers DNA & protein panels, and Pharma Assay Development (PAD) Services.
Key facts about Mission Bio
- Founded Year: 2014
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $120M
- Employee Count: 89 as on Jun 30, 2026
- Investors: Soleus Capital, Mighty Capital and 29 Others
- Latest Funding Round: Series C, Aug 05, 2025, $*****
- Highlight: Editors' Pick
Provider of cell therapies to treat cancer and hematologic conditions. It has developed technology-based solutions for cellular engineering and analysis based on CRISPR-Cas9 biology. It is applying its tools and technologies in markets such as therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. It has developed CAR-T cell therapies for non-Hodgkin lymphoma and myeloid leukemia, and iPSC-derived CAR-NK cell therapies for solid tumors.
Key facts about Caribou Biosciences
- Founded Year: 2011
- Location: Berkeley (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $157M
- Employee Count: 127 as on Jun 30, 2026
- Investors: Adage Capital Management, Janus Henderson Investors and 37 Others
- Latest Funding Round: Post IPO, Jun 29, 2023, $*****
- Highlight: Public
5. ZwitterCo
Zwitter manufactures wastewater treatment systems using membrane technology. Uses nanofiltration technology that claims to stop 98% of organic molecules, enabling efficient water recycling and reducing fouling of membranes in industrial water treatment applications. Has nanoscale pores that are built from self-assembling zwitterionic polymers.
Key facts about ZwitterCo
- Founded Year: 2018
- Location: Somerville (United States)
- Stage: Series B
- Total Funding till date: $102M
- Employee Count: 86 as on Jun 30, 2026
- Investors: Catapult, For Good Ventures and 17 Others
- Latest Funding Round: Series B, Jul 09, 2024, $*****
- Highlight: Editors' Pick
Genoa Ventures' Year-on-Year Investment Trends
Genoa Ventures has invested in 31 companies over the last 11 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Jul 2026, it has made 2 investments in this year. Its most recent first time investment was in Hermes Bioscience and most recent follow-on round was in Epitel.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 2 | 2 |
2025 | 1 | 1 | 2 |
2024 | 1 | 0 | 1 |
2023 | 1 | 0 | 1 |
2022 | 5 | 1 | 6 |
2021 | 3 | 1 | 4 |
2020 | 3 | 2 | 5 |
2019 | 0 | 0 | 0 |
2018 | 2 | 0 | 2 |
2017 | 2 | 0 | 2 |
Genoa Ventures' Investments by Stage
Genoa Ventures has made 13 investments in Series A stage with an average round size of $15.3M, 3 investments in Series B stage with an average round size of $18.8M, 2 investments in Seed stage with an average round size of $1.49M and 1 investment in Series C stage with an average round size of $18.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 13 |
Series B | 3 |
Seed | 2 |
Series C | 1 |
Note: We have considered here, only first round of investments
Genoa Ventures' Investments by Sector
Genoa Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Food and Agriculture Tech and HealthTech. Notably, it has invested in 28 Tech companies, 27 Enterprise (B2B) companies, 8 Software companies and at least 7 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 14 |
High Tech | 6 |
Enterprise Applications | 5 |
Food and Agriculture Tech | 2 |
HealthTech | 2 |
Others | 7 |
Note: We have considered here, only first round of investments
Genoa Ventures' Investments by Geography
Genoa Ventures has made most investments in United States (17), followed by France where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 17 |
France | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Genoa Ventures' recent investments
Genoa Ventures has made 2 investments in 2026 so far - Epitel and Tropic Biosciences.Here are the most recent investments by Genoa Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 28, 2026 | United States | Series B | 5030 | ||
Mar 13, 2026 | United Kingdom | Series C | 9986 | [+9] | |
Nov 18, 2025 | United States | Seed | 7513 | [+1] | |
Jul 10, 2025 | United States | Series B | 3240 | ||
Jun 07, 2024 | United States | Series A | 7704 | [+1] |
IPOs and Publicly Listed companies in Genoa Ventures' Portfolio
1 of Genoa Ventures' portfolio company became public - Caribou Biosciences. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $907MHere are Genoa Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 23, 2021 | Mar 24, 2015 | Series A | 9913 |
Acquired companies in Genoa Ventures' Portfolio
5 companies from Genoa Ventures' portfolio have been acquired. The most recent acquisition was Zymergen in Jul 2022 by Ginkgo Bioworks for $*****.Here are Genoa Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 25, 2022 | - | - | 5751 | |
Jan 21, 2021 | Oct 30, 2018 | Series A | 2411 | |
Jun 04, 2019 | - | - | 3180 | |
Nov 09, 2018 | - | - | 7875 | |
Mar 21, 2016 | - | - | 3229 |
Team profile of Genoa Ventures
Genoa Ventures has a team of 7 members including 3 Partners and 1 Principal located in United States and Switzerland. Genoa Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in Genoa Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | United States | - | ||
Partner | Zurich | - | - | |
Partner | San Jose | - | ||
Principal | San Jose | - | - |
Co-investors of Genoa Ventures
Over the past 11 years, 158 investors have co-invested in Genoa Ventures's portfolio companies. This includes funds and angels.
- Invested before Genoa Ventures: HHS, National Science Foundation and 35 others have invested in rounds before Genoa Ventures. There are 4 companies where HHS has invested before Genoa Ventures and 3 companies where National Science Foundation has invested before Genoa Ventures.
- Top Co-investors of Genoa Ventures: 59 investors entered a company along with Genoa Ventures. These include investors like Vertical Venture Partners (4 companies).
- Invested after Genoa Ventures: A total of 62 investors have invested in Genoa Ventures's portfolio after their investments. Top Investors include NIH (2 companies), HHS (2 companies) and Blue Horizon (1 company).
Recent News related to Genoa Ventures
•
Munich’s UVC adds growth stage with €77M, follows Proxima Fusion’s €2B raiseTech Funding News•Mar 13, 2026•Just Climate, Sucden, Five Seasons Ventures, Genoa Ventures and 6 others
•
•
•
•
Aqtual Raises Over $30M as It Scales Novel cfDNA PlatformBusiness Wire•Jul 10, 2025•Aqtual, Bold Capital Partners, Genoa Ventures, Manta Ray Ventures and 1 other
•
•
•
Ionpath Announces Executive Chair Appointment and CEO PromotionBusiness Wire•Dec 06, 2023•Ionpath, Genoa Ventures
•
Charlottesville’s Brightspec Raises Millions To Commercialize Cutting-edge Scientific InstrumentThe Business Journals•Feb 01, 2023•BrightSpec, Genoa Ventures, Arbor Ventures, Arboretum Ventures and 4 others
•
BrightSpec Raises $18.4M in Series C FinancingFinSMEs•Dec 15, 2022•BrightSpec, Genoa Ventures, Arboretum Ventures, Capital Growth Medvest and 2 others
